HL156A

Clinical data
Other names	IM156, HL271 acetate, UNII-4G3BUV6ZSK
Identifiers
IUPAC name N'-[N'-[4-(trifluoromethoxy)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide
CAS Number	1422365-93-2
PubChem CID	71512108
ChemSpider	92169512
UNII	4G3BUV6ZSK
CompTox Dashboard (EPA)	DTXSID501336867
Chemical and physical data
Formula	C13H16F3N5O
Molar mass	315.300 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CCN(C1)C(=NC(=NC2=CC=C(C=C2)OC(F)(F)F)N)N
InChI InChI=1S/C13H16F3N5O/c14-13(15,16)22-10-5-3-9(4-6-10)19-11(17)20-12(18)21-7-1-2-8-21/h3-6H,1-2,7-8H2,(H4,17,18,19,20) Key:NGFUHJWVBKTNOE-UHFFFAOYSA-N

HL156A is an experimental drug being studied for its potential use in cancer treatment. Chemically, it is derivative of metformin and a potent oxidative phosphorylation inhibitor and AMP-activated protein kinase activating biguanide.^[1][2] Certain types of cancer cells requires oxidative phosphorylation to survive. By targeting it, HL156A might help in improving anticancer therapy.^[3] It is more potent than acadesine or metformin at activating AMP-activated protein kinase.^[2] It is being developed by Hanall Biopharma.^[4]

Research

HL156A is in phase 1 clinical trials in patients with advanced solid tumor and lymphoma.^[5][1] It is also being studied in other conditions such as liver and renal fibrosis,^[2][6] cancer^[7][8] and drug resistance in cancer.^[9] HL176OUT04, a drug with similar pharmacology, has been also developed.^[10]

Pharmacology

This section is missing information about how the AMP-activated protein kinase effect translates to oxidative phosphorylation inhibition; whether these extra effects are downstream or independent of AMPK; whether a direct target is known (AMPK is not the direct target for metformin). Please expand the section to include this information. Further details may exist on the talk page. (July 2022)

Apart from AMP-activated protein kinase activation, it also inhibits expression and activation of insulin-like growth factor-1, protein kinase B, mammalian target of rapamycin (mTOR), and extracellular signal-regulated kinases.^[7][9]

See also

• Phenformin

References